PMID- 9380316
OWN - NLM
STAT- MEDLINE
DCOM- 19971110
LR  - 20190818
IS  - 0029-7844 (Print)
IS  - 0029-7844 (Linking)
VI  - 90
IP  - 4 Pt 1
DP  - 1997 Oct
TI  - Flow cytometric analysis of platelet activation throughout normal gestation.
PG  - 562-8
AB  - OBJECTIVE: To measure platelet activation in normal pregnancy, before and after 
      stimulation with agonists, with a whole blood flow cytometric technique. METHODS: 
      In a cross-sectional study, 5 mL of whole blood was collected from healthy 
      volunteers (nine in the first trimester, ten in the second trimester, 35 in the 
      third trimester, and 32 nonpregnant controls). Platelets were treated with an 
      agonist (thrombin or U-46619, a thromboxane A2 analogue) or buffer and were 
      exposed to saturating concentrations of monoclonal antibodies directed against 
      platelet membrane glycoproteins (GPs): 7E3 (fibrinogen receptor GPIIb/IIIa), S12 
      (alpha granule marker P-selectin), and 6D1 (von Willebrand factor receptor GPIb). 
      Mean fluorescence intensity was determined for 5000 platelets per sample by using 
      a flow cytometer. RESULTS: In the absence of agonist, no significant difference 
      between groups was found in antibody binding. At no stage of pregnancy were 
      circulating activated platelets detected. Platelets from third-trimester subjects 
      bound significantly less 7E3 than platelets of controls or of first- or 
      second-trimester subjects after stimulation with high-dose thrombin (P < .05 for 
      all comparisons). Down-regulation of 6D1 on platelets after stimulation with 
      high-dose U-46619 was significantly greater in third-trimester gravidas than in 
      controls or first-trimester subjects (P < .05). CONCLUSION: Pregnancy does not 
      increase the percentage of activated platelets in the circulation. Platelet 
      reactivity is altered in the third trimester, as evidenced by decreased antibody 
      binding to fibrinogen receptor epitope and enhanced down-regulation of a von 
      Willebrand factor receptor epitope.
FAU - Star, J
AU  - Star J
AD  - Department of Obstetrics and Gynecology, Brown University School of Medicine, 
      Women and Infants Hospital, Providence, Rhode Island, USA.
FAU - Rosene, K
AU  - Rosene K
FAU - Ferland, J
AU  - Ferland J
FAU - DiLeone, G
AU  - DiLeone G
FAU - Hogan, J
AU  - Hogan J
FAU - Kestin, A
AU  - Kestin A
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Obstet Gynecol
JT  - Obstetrics and gynecology
JID - 0401101
RN  - 0 (Hemostatics)
RN  - 76898-47-0 (15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid)
RN  - EC 3.4.21.5 (Thrombin)
SB  - IM
MH  - 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid/pharmacology
MH  - Cross-Sectional Studies
MH  - Female
MH  - Flow Cytometry
MH  - Hemostatics/pharmacology
MH  - Humans
MH  - Platelet Activation/drug effects/*physiology
MH  - Pregnancy/*blood/physiology
MH  - Thrombin/pharmacology
EDAT- 1997/11/05 00:00
MHDA- 1997/11/05 00:01
CRDT- 1997/11/05 00:00
PHST- 1997/11/05 00:00 [pubmed]
PHST- 1997/11/05 00:01 [medline]
PHST- 1997/11/05 00:00 [entrez]
AID - 10.1016/s0029-7844(97)00299-8 [doi]
PST - ppublish
SO  - Obstet Gynecol. 1997 Oct;90(4 Pt 1):562-8. doi: 10.1016/s0029-7844(97)00299-8.